Incyte reports positive Phase III results of ruxolitinib
Top-line results from the Phase III TRuE-AD2 clinical trial have demonstrated that Incyte’s ruxolitinib cream met the primary goal in atopic dermatitis (AD) patients aged above 12 years.
Eli Lilly and Incyte report atopic dermatitis data of baricitinib
Eli Lilly and Incyte have reported positive data from the Phase III BREEZE-AD4 clinical trial performed to assess a combination of baricitinib and topical corticosteroids (TCS) for moderate to severe atopic dermatitis (AD).
Verrica reports positive Phase III results of VP-102 in molluscum
Verrica Pharmaceuticals has reported positive results from the post-hoc pooled analysis of the Phase III CAMP clinical trials of VP-102 in patients with molluscum contagiosum.
Aegle Therapeutics raises funds for DEB skin disorder clinical trial
Biotechnology firm Aegle Therapeutics, which specialises in isolating extracellular vesicles (EVs) secreted by mesenchymal stem cells as therapy, has raised $4m in a funding round led by Boca Raton-based New World Angels.
UCB’s bimekizumab outperforms AbbVie’s Humira in psoriasis patients
The BE SURE study is one of six ongoing clinical trials of bimekizumab in psoriasis and is UCB’s third study that has shown positive results this year.
LEO Pharma’s tralokinumab meets all primary and secondary endpoints in three pivotal trials
Anti-interleukin-13 is in development for the treatment of moderate-to-severe atopic dermatitis.
FDA and NCATS launch CURE ID app for healthcare professionals
The US Food and Drug Administration (FDA) and the National Institutes of Health’s (NIH) National Center for Advancing Translational Sciences (NCATS) have launched a new app called CURE ID for health care professionals.
Future of IL-33 inhibition in atopic dermatitis in doubt
AnaptysBio's etokimab failed to meet its primary endpoint in a Phase IIb study.
Novartis’ Cosentyx sees mixed results from head-to-head with Humira
Although Novartis' Cosentyx showed numerically higher results for its primary endpoint, it failed to demonstrate statistically significant superiority over AbbVie's Humira.